Gordon W Dewald

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Laboratory Geentics and Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:3038-45. 2004
  2. ncbi request reprint Preclinical validation of fluorescence in situ hybridization assays for clinical practice
    Anne E Wiktor
    Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Genet Med 8:16-23. 2006
  3. pmc Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence
    John L Frater
    Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, USA
    Diagn Pathol 3:16. 2008
  4. ncbi request reprint Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia
    Gordon W Dewald
    Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 121:287-95. 2003
  5. pmc Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma
    Gordon W Dewald
    Cytogenetics Laboratory, Mayo Clinic, Rochester, MN 55905, USA
    Blood 106:3553-8. 2005
  6. pmc Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas
    Gordon W Dewald
    Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:801-10. 2009
  7. doi request reprint Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era
    Shernan G Holtan
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:708-13. 2008
  8. ncbi request reprint Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution
    Rafael Santana-Davila
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 32:407-11. 2008
  9. ncbi request reprint Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia
    Stephanie R Fink
    Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 29:253-62. 2005
  10. doi request reprint Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases
    Rafael Santana-Davila
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leuk Res 32:1927-30. 2008

Detail Information

Publications73

  1. ncbi request reprint FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Laboratory Geentics and Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:3038-45. 2004
    ..In contrast, only 40% partial response rate was seen in 10 HES cases. FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis...
  2. ncbi request reprint Preclinical validation of fluorescence in situ hybridization assays for clinical practice
    Anne E Wiktor
    Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Genet Med 8:16-23. 2006
    ..The purpose of this article is to describe a broadly applicable preclinical validation process...
  3. pmc Dysregulated angiogenesis in B-chronic lymphocytic leukemia: morphologic, immunohistochemical, and flow cytometric evidence
    John L Frater
    Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, USA
    Diagn Pathol 3:16. 2008
    ..The extent of enhanced bone marrow angiogenesis in chronic lymphocytic leukemia (CLL) and relationship to proangiogenic factors and prognostic indicators is largely unexplored...
  4. ncbi request reprint Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia
    Gordon W Dewald
    Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 121:287-95. 2003
    ..Importantly, only CD38+ was significantly associated with high-risk FISH categories (+12, 11q- and 17p-) after adjustment for the effects of other variables...
  5. pmc Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma
    Gordon W Dewald
    Cytogenetics Laboratory, Mayo Clinic, Rochester, MN 55905, USA
    Blood 106:3553-8. 2005
    ....
  6. pmc Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas
    Gordon W Dewald
    Division of Laboratory Genetics, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 84:801-10. 2009
    ..To use fluorescence in situ hybridization (FISH) to visualize genetic abnormalities in interphase cell nuclei (interphase FISH) of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas...
  7. doi request reprint Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era
    Shernan G Holtan
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:708-13. 2008
    ..Additional important prognostic factors not taken into account by the IPSS include the baseline erythrocyte indices, lymphocyte count, and clonal burden...
  8. ncbi request reprint Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution
    Rafael Santana-Davila
    Division of Hematology, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 32:407-11. 2008
    ..We conclude that del(5q), although most prevalent in MDS, is seen across the spectrum of myeloid disorders including MPD and its occurrence in lymphoid disorders might signify, for the most part, an occult myeloid clone...
  9. ncbi request reprint Fluorescent-labeled DNA probes applied to novel biological aspects of B-cell chronic lymphocytic leukemia
    Stephanie R Fink
    Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 29:253-62. 2005
    ..Deletions in IGHv occurred in 25% of patients and correlated with IGHv gene expression. Probes for 6q23 detected more deletions in 6q than probes for 6q21...
  10. doi request reprint Primary myelofibrosis is the most frequent myeloproliferative neoplasm associated with del(5q): clinicopathologic comparison of del(5q)-positive and -negative cases
    Rafael Santana-Davila
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Leuk Res 32:1927-30. 2008
    ..When used, lenalidomide therapy induced hematological and cytogenetic remissions in del(5q)-positive PMF. The current study identifies PMF as another del(5q)-associated myeloid malignancy with characteristic megakaryocyte morphology...
  11. ncbi request reprint The incidence and anatomic site specificity of chromosomal translocations in primary extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) in North America
    Ellen D Remstein
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester MN 55905, USA
    Am J Surg Pathol 30:1546-53. 2006
    ..Differences in incidence and anatomic site specificity of translocations between North American and non-North American cases may reflect geographic variability of infectious or other etiologic factors...
  12. ncbi request reprint Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemia
    Stephanie R Fink
    Cytogenetics Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 167:177-81. 2006
    ..Translocations or isochromosome formations at sites of low-copy DNA repeats in 17p10 to 17p12 appear to be the mechanism for the loss of TP53 in B-CLL...
  13. ncbi request reprint Metaphase cells with normal G-bands have cryptic interstitial deletions in 13q14 detectable by fluorescence in situ hybridization in B-cell chronic lymphocytic leukemia
    Kimberly J Stockero
    Cytogenetics Laboratory, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 166:152-6. 2006
    ..As a result of this study, we report evidence that B-CLL metaphases with 13q- are not detected because these deletions are often cryptic and not visible by standard G-banding...
  14. pmc Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
    Neil E Kay
    Mayo Clinic, Stabile 628, 200 First St SW, Rochester, MN 55905, and The Ohio State University, Columbus, USA
    Blood 109:405-11. 2007
    ....
  15. ncbi request reprint Clinical and biologic implications of recurrent genomic aberrations in myeloma
    Rafael Fonseca
    Mayo Cinic Division of Hematology, Department of Laboratory Medicine, Rochester, MN 55905, USA
    Blood 101:4569-75. 2003
    ..More importantly it provides further compelling evidence that MM is composed of subgroups of patients categorized according to their underlying genomic aberrations...
  16. pmc Percentage of smudge cells on routine blood smear predicts survival in chronic lymphocytic leukemia
    Grzegorz S Nowakowski
    Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 27:1844-9. 2009
    ..In this study, we evaluated whether the smudge cell percentage on a blood smear predicted survival of CLL patients...
  17. ncbi request reprint Frequency, hematopathology, and detection of a new isodicentric variant of deletion 20q
    Stephanie A Smoley
    Division of Laboratory Genetics, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 173:144-9. 2007
    ..This study shows ider(20q) is common in clinical practice--1/10th the incidence of del(20q)--and is strongly associated with myelodysplasia and acute myeloid leukemia...
  18. ncbi request reprint Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide
    Ying S Zou
    Cytogenetics and Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Res 31:1185-9. 2007
    ..FISH did not detect anomalies other than deletion 5q in 31 patients. This study suggests FISH is useful to detect deletion 5q, but is not a substitute for conventional cytogenetics...
  19. pmc Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group
    Mark R Litzow
    Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 148:217-25. 2010
    ..We conclude that none of these three regimens were effective enough in the treatment of high-risk relapsed or refractory AML to warrant further study. This trial was registered at http://www.clinicaltrials.gov as #NCT00005962...
  20. pmc Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients
    Renee C Tschumper
    Department of Immunology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Clin Invest 118:306-15. 2008
    ..In addition, these data support the concept that antigen-driven selection of specific Ig receptors plays a role in the clinical course of B-CLL...
  21. ncbi request reprint Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients
    Rafael Fonseca
    Mayo Clinic Department of Hematology and Internal Medicine, Minneapolis, MN 55905, USA
    Blood 99:3735-41. 2002
    ..These patients do not have a worsened prognosis as previously thought...
  22. ncbi request reprint Genomic abnormalities in monoclonal gammopathy of undetermined significance
    Rafael Fonseca
    Division of Hematology and Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 100:1417-24. 2002
    ..Similar translocations are found in both MGUS and MM, including t(4;14)(p16.3;q32) and t(14;16)(q32;q23). Moreover, Delta 13 is common in MGUS and unlikely to play a predominant role in the evolution of MGUS to MM...
  23. ncbi request reprint Prognostic diversity among cytogenetic abnormalities in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 104:1656-60. 2005
    ..The current prospective study addresses this issue in the context of currently accepted independent prognostic variables...
  24. ncbi request reprint The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
    Rafael Fonseca
    Mayo Clinic Division of Hematology, The Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Blood 102:2562-7. 2003
    ..The classification of MM into hyperdiploidy and nonhyperdiploidy is dictated largely by the recurrent (primary) IgH translocations in the latter...
  25. ncbi request reprint Clonal cytogenetic abnormalities in bone marrow specimens without clear morphologic evidence of dysplasia: a form fruste of myelodysplasia?
    David P Steensma
    Department of Internal Medicine, Division of Hematology, Mayo Clinic Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 27:235-42. 2003
    ..Continued follow-up of this heterogeneous cohort and further studies of similar patients will more clearly define the disease processes and prognosis for this constellation of laboratory findings...
  26. ncbi request reprint Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia
    Tait D Shanafelt
    Mayo Clinic College of Medicine, Department of Internal Medicine, Division of Hematology, Rochester, MN 55905, USA
    J Clin Oncol 24:4634-41. 2006
    ..There are minimal prospective data on the clinical utility of the widely used hierarchical FISH prognostic categories in patients with newly diagnosed early-stage CLL or the frequency of clonal evolution as determined by interphase FISH...
  27. ncbi request reprint Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia
    Terra L Reeder
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:1981-3. 2003
    ..The current study provides direct evidence for the clonal involvement of both B and T lymphocytes in MMM. A larger study is needed to clarify the relevance of the observed interpatient heterogeneity in clonal constitution...
  28. ncbi request reprint Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment
    Ayalew Tefferi
    Department of Internal Medicine and Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 80:390-402. 2005
    ..These issues are discussed within the context of clinical practice...
  29. ncbi request reprint Philadelphia chromosome mosaicism at diagnosis in chronic myeloid leukemia: clinical correlates and effect on imatinib mesylate treatment outcome
    Andrew P Landstrom
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 48:2137-40. 2007
    ..Multivariable analysis identified Ph mosaicism as a risk factor for shortened survival. Due to the small sample size, the current preliminary observations require validation in a larger group of patients...
  30. doi request reprint CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential
    Tait D Shanafelt
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Br J Haematol 140:537-46. 2008
    ..Importantly, anti-CD49d antibodies are already approved for treatment of other human diseases. Clinical testing of anti-CD49d therapy in CLL appears warranted...
  31. ncbi request reprint Respective clustering of unfavorable and favorable cytogenetic clones in myelofibrosis with myeloid metaplasia with homozygosity for JAK2(V617F) and response to erythropoietin therapy
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 106:1739-43. 2006
    ..For the current study, the authors explored the relation between specific cytogenetic clones and JAK2(V617F) mutational status in patients with MMM and the effects on treatment response to erythropoietin (Epo)...
  32. ncbi request reprint Clinical correlates of submicroscopic deletions involving the ABL-BCR translocation region in chronic myeloid leukemia
    Yinlee Yoong
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 74:124-7. 2005
    ..These results are contrary to previous reports that suggested inferior survival as well as poor response to alpha interferon therapy in CML patients carrying der(9) deletions...
  33. ncbi request reprint Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis
    David Dingli
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 106:1985-9. 2006
    ..Such information is particularly crucial for management decisions in transplant-eligible patients...
  34. ncbi request reprint Adult B-cell lymphomas with burkitt-like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior
    Rebecca F McClure
    Department of Laboratory Medicine and Pathology, Divisions of Anatomic Pathology and Hematopathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 29:1652-60. 2005
    ....
  35. pmc Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium
    Stephanie A Smoley
    Cytogenetics, Division of Laboratory Genetics, Department of Laboratory Medicine, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 203:141-8. 2010
    ..Individual laboratories can help by closely following rigorous quality assurance guidelines to ensure accurate and consistent FISH studies in their clinical practice and research...
  36. pmc Mucosa-associated lymphoid tissue lymphomas with t(11;18)(q21;q21) and mucosa-associated lymphoid tissue lymphomas with aneuploidy develop along different pathogenetic pathways
    Ellen D Remstein
    Division of Anatomic Pathology and Hematopathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Pathol 161:63-71. 2002
    ..Both t(11;18) and aneuploidy were seen disproportionately in lung, and both were associated with recurrent disease...
  37. ncbi request reprint A novel tricolor, dual-fusion fluorescence in situ hybridization method to detect BCR/ABL fusion in cells with t(9;22)(q34;q11.2) associated with deletion of DNA on the derivative chromosome 9 in chronic myelocytic leukemia
    Stephanie A Smoley
    Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 148:1-6. 2004
    ....
  38. ncbi request reprint Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma
    Gordon W Dewald
    Division of Laboratory Genetics, Mayo Clinic, Rochester, MN, USA
    Int J Hematol 76:65-74. 2002
    ..New methods to extract individual nuclei from paraffin-embedded tissue are now available which permit the use of interphase FISH to detect important chromosome anomalies in lymphoma...
  39. ncbi request reprint New highly sensitive fluorescence in situ hybridization method to detect PML/RARA fusion in acute promyelocytic leukemia
    Stephanie R Brockman
    Division of Laboratory Genetics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 145:144-51. 2003
    ..In addition, this FISH method can detect all alternate translocations involving RARA and not PML. This FISH method can be used both for the accurate diagnosis of APL and to monitor low levels of disease in treated patients...
  40. ncbi request reprint Cytogenetics of chronic myeloproliferative disorders and related myelodysplastic syndromes
    Adewale Adeyinka
    Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic Rochester, 200 First Street Southwest, Rochester MN 55905, USA
    Hematol Oncol Clin North Am 17:1129-49. 2003
    ..FISH techniques are useful for MPD to study inadequate bone marrow or blood specimens and to monitor disease status among patients with known chromosome anomalies, but they are not more sensitive than conventional chromosome studies...
  41. ncbi request reprint CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 102:3093-6. 2003
    ..Screening for the FIP1L1-PDGFRA rearrangement and Asp816Val mutation will advance rational therapy decisions in SMCD...
  42. pmc A new method to extract nuclei from paraffin-embedded tissue to study lymphomas using interphase fluorescence in situ hybridization
    Sarah F Paternoster
    Division of Laboratory Genetics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Am J Pathol 160:1967-72. 2002
    ..This FISH technique is useful to detect chromosome anomalies with high sensitivity and specificity in paraffin-embedded tissue and may provide important diagnostic and prognostic genetic information...
  43. ncbi request reprint Molecular cytogenetic studies for hematological malignancies
    Gordon W Dewald
    Cytogenetics Laboratory, Mayo Clinic, Rochester, MN, USA
    Cancer Treat Res 121:69-112. 2004
  44. ncbi request reprint Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study
    Rafael Fonseca
    Department of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 62:715-20. 2002
    ..03). The presence of Delta13 is an important and independent adverse prognostic factor in newly diagnosed MM and is associated with specific biological features...
  45. ncbi request reprint Primary myelodysplastic syndrome with normal cytogenetics: utility of 'FISH panel testing' and M-FISH
    Rhett P Ketterling
    Department of Laboratory Medicine and Pathology, Mayo Clinic Foundation, 200 First Street S W, Rochester, MN 55905, USA
    Leuk Res 26:235-40. 2002
    ..These findings confirm standard cytogenetics as an excellent technique in identifying the common chromosomal abnormalities associated with MDS and suggest limited utility for either a FISH panel test or M-FISH in primary MDS...
  46. ncbi request reprint The prognostic significance of trisomy 8 in patients with acute myeloid leukemia
    Michelle A Elliott
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Leuk Lymphoma 43:583-6. 2002
    ..The presence of +8 did not appear to adversely affect the outcome of patients with favorable karyotypes...
  47. ncbi request reprint Prevalence, breakpoint distribution, and clinical correlates of t(5;12)
    Patricia T Greipp
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Genet Cytogenet 153:170-2. 2004
    ..1) and ACMD,t(5;12)(q31;q24.1)]. The t(5;12) is a rare, myelocytic-exclusive cytogenetic abnormality with a breakpoint-specific association with eosinophilia or monocytosis...
  48. ncbi request reprint Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:3854-6. 2002
    ..In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit...
  49. ncbi request reprint Hematologic malignancies, critical genes and representative pictures for 166 chromosome anomalies
    Victor J Mahaffey
    Division of Laboratory Genetics, Cytogenetics Laboratory, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 28:1351-6. 2004
  50. ncbi request reprint A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia
    Mark R Litzow
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St S W, Rochester, MN 55905, USA
    Haematologica 91:1105-8. 2006
    ..One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL...
  51. ncbi request reprint Primer on medical genomics part II: Background principles and methods in molecular genetics
    Ayalew Tefferi
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:785-808. 2002
    ....
  52. ncbi request reprint Interphase FISH studies of chronic myeloid leukemia
    Gordon W Dewald
    Laboratory Medicine and Medical Genetics, Mayo Clinic, Rochester, MN, USA
    Methods Mol Biol 204:311-42. 2002
  53. ncbi request reprint Primer on medical genomics. Part XI: Visualizing human chromosomes
    Jack L Spurbeck
    Cytogenetics Laboratory, Division of Laboratory Genetics, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
    Mayo Clin Proc 79:58-75. 2004
    ..The clinical diagnosis, prognosis, and response to treatment can be established for many malignant diseases. Cytogenetic methods provide an important diagnostic tool for clinical practice...
  54. ncbi request reprint Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q
    Azra Raza
    Rush University Medical Center, Chicago, IL, USA
    Blood 111:86-93. 2008
    ..Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1-risk MDS who lack the deletion 5q karyotypic abnormality...
  55. ncbi request reprint Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study
    Athena M Cherry
    Department of Pathology, Stanford Hospital and Clinics, Stanford, CA 94305, USA
    Leuk Res 27:1085-90. 2003
    ..In addition, it appears that interphase FISH studies are nearly as sensitive as cytogenetic analyses and can be a useful tool in studying bone marrow aspirates where cytogenetic analysis is not possible...
  56. ncbi request reprint Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia
    Martin L Lesser
    North Shore Long Island Jewish Research Institute, Manhasset, NY, USA
    Cancer Genet Cytogenet 137:79-84. 2002
    ..The results indicate that mixing data of different methods to measure treatment response within or between patients may be misleading clinical index...
  57. doi request reprint Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression
    Tait D Shanafelt
    J Clin Oncol 26:e5-6. 2008
  58. doi request reprint Peripheral blood cytogenetic studies in myelofibrosis: overall yield and comparison with bone marrow cytogenetic studies
    Kebede Hussein
    Division of Hematology, Rochester, MN, United States
    Leuk Res 32:1597-600. 2008
    ..These results suggest that PB can be considered as an alternative to BM for cytogenetic studies as currently used in MF but additional prospective studies are needed to support change in practice...
  59. pmc Expression of TCL-1 as a potential prognostic factor for treatment outcome in B-cell chronic lymphocytic leukemia
    Rebekah L Browning
    Ohio State University, Columbus, OH, United States
    Leuk Res 31:1737-40. 2007
    ..199) were noted with lower TCL-1 expression. These data suggest TCL-1 expression may help predict treatment outcome in CLL patients following chemoimmunotherapy, and examination in larger studies is warranted...
  60. ncbi request reprint Chronic lymphocytic leukemia FISH panel: impact on diagnosis
    Beverly P Nelson
    Department of Pathology, Feinberg Medical School, Northwestern University, Chicago, IL 60611 2908, USA
    Am J Clin Pathol 128:323-32. 2007
    ..Morphologic features were atypical for CLL in 2 cases with IGH fusion (BCL11A and BCL3). The FISH CLL panel is useful to identify prognostic aberrations and to clarify diagnosis in cases with unusual morphologic features...
  61. ncbi request reprint The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
    Frederick R Appelbaum
    Southwest Oncology Group Statistical Center, Seattle, WA, USA
    Br J Haematol 135:165-73. 2006
    ..021), and in patients with t(8;21) (P = 0.025). OS was superior in patients who received regimens with high-dose cytarabine, a combination of fludarabine and intermediate-dose cytarabine, or haematopoietic cell transplantation...
  62. ncbi request reprint Utility of interphase FISH to stratify patients into cytogenetic risk categories at diagnosis of AML in an Eastern Cooperative Oncology Group (ECOG) clinical trial (E1900)
    Gail H Vance
    Medical and Molecular Genetics, Indiana University School of Medicine, 975 W Walnut Street IB 264, Indianapolis, IN 46202, USA
    Leuk Res 31:605-9. 2007
    ....
  63. ncbi request reprint Cytogenetic abnormalities can change during the course of the disease process in chronic lymphocytic leukemia
    Tait D Shanafelt
    J Clin Oncol 24:3218-9; author reply 3219-20. 2006
  64. ncbi request reprint Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia
    David Dingli
    Division of Hematology and Department of Internal Medicine, Mayo Clinic Rochester, MN, USA
    Br J Haematol 130:229-32. 2005
    ..In a preliminary fluorescence in situ hybridization study, the breakpoints on chromosome 6 in two additional cases were found to be telomeric to the gene for 51 kDa FK506-binding protein (FKBP51)...
  65. ncbi request reprint Delineation of the minimal commonly deleted segment and identification of candidate tumor-suppressor genes in del(9q) acute myeloid leukemia
    David A Sweetser
    Department of Pediatrics, Massachusetts General Hospital, 55 Fruit Street Jackson 904, Boston, MA 02114, USA
    Genes Chromosomes Cancer 44:279-91. 2005
    ..The results of our studies are consistent with a model of tumor suppression mediated by haploinsufficiency of critical genes in del(9q) AML...
  66. ncbi request reprint Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial
    Anthony V Moorman
    Leukaemia Research Cytogenetics Group, Cancer Sciences Division, University of Southampton, Southampton General Hospital, Southampton, UK
    Blood 109:3189-97. 2007
    ....
  67. pmc The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes
    David P Steensma
    Mayo Clinic and Mayo Clinic College of Medicine, Rochester MN 55905, USA
    Blood 106:1207-9. 2005
    ..The current observation strengthens the specific association between JAK2 V617F and classic MPD, but also suggests an infrequent occurrence in other myeloid disorders...
  68. ncbi request reprint Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997
    Ian W Flinn
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA
    J Clin Oncol 25:793-8. 2007
    ..E2997 is a phase III randomized Intergroup trial comparing fludarabine and cyclophosphamide (FC arm) versus fludarabine (F arm) alone in patients receiving their first chemotherapy regimen for CLL...
  69. ncbi request reprint Proficiency testing for laboratories performing fluorescence in situ hybridization with chromosome-specific DNA probes
    James T Mascarello
    Genetic Services, Children s Hospital, San Diego, Calif 92123, USA
    Arch Pathol Lab Med 126:1458-62. 2002
    ....
  70. ncbi request reprint Problems with ISCN FISH Nomenclature make it not practical for use in clinical test reports or cytogenetic databases [corrected]
    James T Mascarello
    Genzyme Genetics, Santa Fe, New Mexico 87505, USA
    Genet Med 5:370-7. 2003
    ..To assess the extent and the sources of variation in ISCN nomenclature used by participants in CAP/ACMG surveys dealing with fluorescence in situ hybridization (FISH)...
  71. pmc Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission
    Martin S Tallman
    Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
    Blood 110:409-17. 2007
    ..However, treatment-related mortality was high. Matched unrelated donor HSCT should be considered for all patients with unfavorable cytogenetics who lack a suitable HLA-matched sibling donor...
  72. pmc Guidance for fluorescence in situ hybridization testing in hematologic disorders
    Daynna J Wolff
    Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, South Carolina, USA
    J Mol Diagn 9:134-43. 2007
    ....
  73. ncbi request reprint Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995)
    Peter A Cassileth
    University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA
    Leuk Lymphoma 46:55-61. 2005
    ..Nevertheless, intensive post-remission therapy was well tolerated, no treatment-related mortality occurred with autologous PBSCT, and disease-free survival and overall survival were lengthy...